Form 483

AstraZeneca Pharmaceuticals LP Form 483, 2022-07-22

FDA issued a Form 483 to AstraZeneca Pharmaceuticals LP on 2022-07-22 with 3 public-safe observations.

483· Form 483 issuedBiologics3 observations

AstraZeneca Pharmaceuticals LP · Philadelphia, United States · Issued July 22, 2022

Overview

  • 3 public-safe observations are available for this inspection.
  • 3 structured CFR citations are represented.
  • 1 investigator is tied to this Form 483.

Inspectional observations

Each observation cites the regulation FDA found the firm out of compliance with.

22 Jul 2022
21 CFR 211.113(b)

Procedures for sterile drug products

Cited by Unnee Ranjan

22 Jul 2022
21 CFR 211.192

Extent of discrepancy, failure investigations

Cited by Unnee Ranjan

22 Jul 2022
21 CFR 211.63

Equipment Design, Size and Location

Cited by Unnee Ranjan

Inspected site

APAstraZeneca Pharmaceuticals LPPhiladelphia, United States

Inspection team

Cited regulations

CFR citations associated with this Form 483.

CitationWhat it coversCited
21 CFR 211.113(b)Cited across public-safe Form 483 observations1x
21 CFR 211.192Cited across public-safe Form 483 observations1x
21 CFR 211.63Cited across public-safe Form 483 observations1x

Source document

PDF
PDF available

Form 483 source document

The source document is available to authorized Atlas users.

Full 483 report

Get the verbatim text of all 3 observations

The source PDF, so your team sees exactly what was cited and how it was answered.

  • The site's full inspection history around this Form 483
  • Whether these citations escalated to a warning letter
  • The investigators involved and the citations they repeat elsewhere